Unique ID issued by UMIN | UMIN000043849 |
---|---|
Receipt number | R000049585 |
Scientific Title | The validation study of the value of serum procalcitonin for predicting the prognosis of patients with pulmonary tuberculosis. |
Date of disclosure of the study information | 2021/04/06 |
Last modified on | 2024/04/09 10:13:05 |
The validation study of the value of serum procalcitonin for predicting the prognosis of patients with pulmonary tuberculosis.
The validation study of the value of serum procalcitonin for predicting the prognosis of patients with pulmonary tuberculosis.
The validation study of the value of serum procalcitonin for predicting the prognosis of patients with pulmonary tuberculosis.
The validation study of the value of serum procalcitonin for predicting the prognosis of patients with pulmonary tuberculosis.
Japan |
Pulmonary tuberculosis
Medicine in general | Pneumology | Infectious disease |
Others
NO
This study is validating the prognostic value of serum procalcitonin in pulmonary tuberculosis, which has been shown in a preceding study (J Infect Dis. 2020 May 23:jiaa275. doi: 10.1093/infdis/jiaa275).
Others
Predicting the prognosis
In-hospital mortality
Length of hospital stay
Duration of sputum culture conversion of acid fast bacilli
Observational
18 | years-old | <= |
Not applicable |
Male and Female
Newly diagnosed active pulmonary tuberculosis, with or without extrapulmonary tuberculosis; and no treatment with antituberculosis agents on admission.
Disseminated tuberculosis (ie, positive M. tuberculosis PCR or culture test results for urine, blood, or cerebrospinal fluid) or a history of tuberculosis treatment in the 10 years before recruitment.
160
1st name | Takeshi |
Middle name | |
Last name | Osawa |
Japan Anti-Tuberculosis Association (JATA), Fukujuji Hospital
Department of Respiratory Medicine
2040022
3-1-24 Matsuyama, Kiyose-shi, Tokyo 204-8522, Japan
0424914111
take4.osawa@nifty.com
1st name | Takeshi |
Middle name | |
Last name | Osawa |
Japan Anti-Tuberculosis Association (JATA), Fukujuji Hospital
Department of Respiratory Medicine
2040022
3-1-24 Matsuyama, Kiyose-shi, Tokyo 204-8522, Japan
0424914111
take4.osawa@nifty.com
Japan Anti-Tuberculosis Association (JATA), Fukujuji Hospital
There is no funding source.
Other
FUJIFILM Wako Pure Chemical Corporation
Japan Anti-Tuberculosis Association (JATA), Fukujuji Hospital
3-1-24 Matsuyama, Kiyose-shi, Tokyo 204-8522, Japan
0424914111
shom@fukujuji.org
NO
2021 | Year | 04 | Month | 06 | Day |
https://pubmed.ncbi.nlm.nih.gov/37726072/
Partially published
https://pubmed.ncbi.nlm.nih.gov/37726072/
165
The data from 252 patients in the development cohort and 165 patients in the validation cohort were analyzed, of whom 39 (15.5%) and 17 (10.3%), respectively, died in
the hospital. The disease severity score (named the AHL score) included three clinical parameters: activities of daily living (semi-dependent, 1 point; totally dependent, 2 points);
hypoxemia (1 point), and lymphocytes (< 720/mL, 1 point).
2024 | Year | 04 | Month | 09 | Day |
None of these patients was co-infected with HIV. Patient characteristics were similar in both cohorts, except that more patients in the validation cohort had cavitary lesions, extrapulmonary lesions, and were smear-positive for sputum AFB. Among the patients in the development cohort, 39 patients (15.5%) died in the hospital, and 213 patients (84.5%) survived following treatment (Table 2). Among the patients in the validation cohort, 17 (10.3%) died in the hospital, and 148 (89.7%) survived following treatment.
A total of 406 and 290 patients were eligible according to the inclusion criteria in the development cohort and validation cohort, respectively. After the exclusion criteria were applied, the data from 252 and 165 patients who gave written informed consent were analyzed.
Not applicable
All-cause in-hospital mortality
No longer recruiting
2020 | Year | 09 | Month | 02 | Day |
2020 | Year | 11 | Month | 12 | Day |
2021 | Year | 03 | Month | 01 | Day |
2023 | Year | 03 | Month | 31 | Day |
The primary endpoint is patients death in hospital.
The study participants will be observed until leaving hospital.
2021 | Year | 04 | Month | 06 | Day |
2024 | Year | 04 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049585
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |